Clinical Trial Update: Testing the Safety of CB-5339 in Patients With Cancer [Phase 1]

View source ↗

Summary

The Phase 1 clinical trial of CB-5339 in cancer patients has been withdrawn, with no study results reported.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Aggressive Non-hodgkin Lymphoma
• Indolent Non-hodgkin Lymphoma
• Malignant Solid Neoplasm

Drugs mentioned

• CB-5339 (CB-5339)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Aggressive Non-Hodgkin Lymphoma, Indolent Non-Hodgkin Lymphoma | Phase 1 | Status: WITHDRAWN